Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

Arcutis today announced new patient-reported outcome data demonstrating that ZORYVE cream 0.15% improved the impact of AD on patients and families.
October 23, 2024 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

Quarterly investor conference call and webcast is scheduled for Wednesday, November 6 at 4:30 p.m. ETArcutis management will also participate in the Guggenheim Securities Healthcare Innovation...
October 18, 2024 08:20 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Arcutis today announced regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis.
October 04, 2024 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
September 25, 2024 01:00 ET | Source: Arcutis Biotherapeutics, Inc.

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

Arcutis today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials.
September 24, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Arcutis today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3% for scalp and body psoriasis.
September 19, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

ZORYVE® (roflumilast) cream 0.15% improved atopic dermatitis (AD) across multiple efficacy endpoints while demonstrating favorable safety and tolerabilityAcross both studies, approximately 31% of...
September 05, 2024 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
September 05, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

Arcutis today announced the enrollment of the last subject in the Phase 1b study evaluating ARQ-255 for the treatment of alopecia areata.
August 28, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis today announced results from the INTEGUMENT-OLE long-term open-label study of once-daily roflumilast cream 0.05%.